Pediatrix Medical Group, Inc. - Q1 2007 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2007. Pediatrix Medical Group, Inc. is a provider of pediatric medical services. The filing was delayed due to an independent review of the Company's historical stock option granting practices. The financial statements include restated information related to this review and the adoption of new accounting standards (FIN 48) effective January 1, 2007.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Patient Service Revenue | $214.5 million | $187.7 million |
| Net Income | $25.6 million | $23.4 million |
| Diluted EPS | $0.51 | $0.48 |
| Operating Margin | 18.0% | 20.0% |
| Cash and Cash Equivalents | $71.6 million | $4.5 million |
| Working Capital | $125.0 million | $80.3 million (Dec 2006) |
| Net Cash Used in Operating Activities | ($30.8 million) | ($9.8 million) |
| Long-Term Debt | $0.2 million | $0.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14.3% year-over-year. This was driven by a 10.7% increase in same-unit revenue (due to pricing/reimbursement improvements and volume growth) and $7.3 million from acquisitions.
- Expense Increases: Operating expenses rose significantly, primarily due to:
- Practice salaries and benefits increased 16.3% due to new hires, incentive compensation, and costs related to stock option measurement date revisions.
- General and administrative expenses increased 22.7%, largely driven by professional fees for the stock option review and costs to cover IRS Section 409A tax obligations.
- Cash Flow: Net cash used in operating activities increased to $30.8 million (from $9.8 million in Q1 2006). This is a seasonal occurrence primarily due to the payment of annual performance-based incentive compensation and Thrift and Profit Sharing Plan contributions in the first quarter.
- Investments: Short-term investments decreased from $65.7 million to $17.2 million as the Company liquidated variable rate demand bonds.
Guidance, Outlook, Risks, and Unusual Items
- Stock Option Review & 409A Costs: The Company incurred approximately $6.4 million in costs to cover IRS Section 409A tax obligations and other payments to employees resulting from the revision of stock option measurement dates. Additionally, $1.5 million in professional fees were incurred for the stock option review. These items reduced the operating margin.
- Legal Proceedings: The SEC has commenced a formal investigation into the Company's stock option practices. The Company is cooperating with the SEC and the U.S. Attorney's office. The outcome is unpredictable.
- Corporate Integrity Agreement: The Company is subject to a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG) following a $25.1 million settlement regarding neonatal services. Failure to comply could result in exclusion from federal healthcare programs.
- Acquisitions: The Company acquired two physician group practices in Q1 2007 and one subsequent to the period end. Pro forma results suggest the acquisitions were accretive.
- Share Repurchase: In August 2007, the Board authorized a $100 million share repurchase program.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing SEC investigation into stock option practices.
- Confirm the Company's continued compliance with the Corporate Integrity Agreement and the OIG.
- Monitor the resolution of the $42.0 million liability for unrecognized tax benefits and the impact of FIN 48 adoption.
- Assess the sustainability of same-unit revenue growth given the reliance on reimbursement rate improvements.
- Review the execution of the new $100 million share repurchase program and its impact on capital allocation.